

## TABLE OF CONTENTS

CHAPTER NO.	TITLE	PAGE NO
	<b>ABSTRACT</b>	vi
	<b>LIST OF TABLES</b>	Xiv
	<b>LIST OF FIGURES</b>	Xv
	<b>LIST OF SYMBOLS AND ABBREVIATIONS</b>	Xvi
1	<b>INTRODUCTION</b>	1
2	<b>SCOPE AND OBJECTIVES</b>	6
3	<b>REVIEW OF LITERATURE</b>	8
3.1	AGEING	8
3.2	THEORIES OF AGEING	8
3.3	BRAIN AGEING	10
3.4	DEMENTIA	11
3.4.1	PREVALENCE	12
3.5	BEHAVIORAL DYSFUNCTION IN AGEING AND SDAT	13
3.6	ALTERATIONS IN NEUROTRANSMISSION SYSTEM IN AGEING AND SDAT	13
3.7	OXIDATIVE STRESS IN BRAIN AGEING IN SDAT	15
3.8	INFLAMMATION IN BRAIN AGEING AND SDAT	17
3.9	OTHER MECHANISMS	19
3.10	ANIMAL MODEL FOR AGEING AND SDAT	19
3.11	CURRENT DRUG STRATEGIES FOR COGNITIVE IMPAIRMENT AND SDAT	21
3.12	HEALTHY BRAIN AGEING AS A NEUROPROTECTIVE STRATEGY FOR PREVENTION OF SDAT	22
3.13	PLANTS AS NEUROPROTECTIVE AGENTS	22

3.14	<i>BACOPA MONNIERI</i>	24
3.15	<i>DIOSCOREA BULBIFERA</i>	29
3.16	<i>HIPPOPHAE RHAMNOIDES</i>	31
4	<b>STANDARDISATION AND QUALITY CONTROL</b>	
4.1	INTRODUCTION	37
4.2	METHODOLOGY	38
	4.2.1 Evaluation of Organoleptic Properties	38
	4.2.2 Preliminary phytochemical screening of polyherbal formulation	38
	4.2.3 Test for alkaloids	39
	4.2.4 Test for carbohydrates	39
	4.2.5 Test for steroids and sterols	49
	4.2.6 Test for glycosides	40
	4.2.7 Test for Saponins	40
	4.2.8 Test for flavonoids	40
	4.2.9 Test for tannins and phenolic compounds	40
	4.2.10 Test for protein and amino acid	41
	4.2.11 Test for fixed oils	41
	4.2.12 Determination of moisture content	41
	4.2.13 Determination of Ash values	42
	4.2.14 Determination of extractive values	42
	4.2.15 Total phenolic content	43
	4.2.16 Total flavonoid content	43
	4.2.17 Heavy metal analysis	43
	4.2.18 Determination of Microbial load	44
4.3	RESULTS AND DISCUSSION	44
	4.3.1 Ash Values and Moisture content	46
	4.3.2 Extractive values	46
	4.3.3 Total phenolic content and Total flavonoid content of the polyherbal formulation	47
	4.3.4 Heavy metal analysis	47

	4.3.5 Microbial load Analysis	47
	4.4 Instrumentation	48
	4.4.1 Quantification of biomarkers from the formulation	48
	4.4 CONCLUSION	50
5	<b>INVITRO ANTIOXIDANT AND NEUROPROTECTIVE ACTIVITY OF POLYHERBAL FORMUALTION</b>	
	5.1 INTRODUCTION	51
	5.2 METHODOLOGY	52
	5.2.1 Antioxidant assays	52
	5.2.2 DPPH radical scavenging activity	52
	5.2.3 Hydroxyl radical scavenging assay	52
	5.2.3 FTC assay	53
	5.4 <i>IN VITRO</i> NEUROPROTECTIVE ACTIVITY	53
	5.3.1 Cell line maintenance	53
	5.3.2 Cell viability assay	53
	5.3.2.1 MTT assay	53
	5.3.2.2 Propidium iodide Assay	54
	5.3.2.3 DCFDA assay	54
	5.5 RESULTS	55
	5.4.1 Free radical scavenging activity of polyherbal formulation	55
	5.4.2 Effect of the polyherbal formulation sample on IMR32 cell line	56
	5.4.3 Neuroprotective effect of the polyherbal formulation on H <sub>2</sub> O <sub>2</sub> cytotoxicity	57
	5.4.4 Effect of the polyherbal formulation on intracellular ROS activity	58
	5.6 DISCUSSION	59
	5.7 CONCLUSION	60
6	<i>IN VIVO</i> NEUROPROTECTIVE PROPERTY ACTIVITY OF POLYHERBAL FORMUALTION ON AGED RATS	61

6.1	INTRODUCTION	61
6.2	METHODOLOGY	61
	6.2.1 Experimental animals	62
	6.2.2 Experimental model	62
	6.2.3 Estimation of neurotransmitters content	62
	6.2.3.1 Acetylcholine	62
	6.2.3.2 Biogenic amines	63
	6.2.3.3 Acetylcholinesterase (AChE) Inhibition Activity	64
	6.2.3.4 Estimation of lipofuscin content	64
	6.2.3.5 Oxidative stress markers	64
	6.2.3.5.1 Lipid Peroxidation (LPO)	64
	6.2.3.5.2 Total glutathione content (GSH)	65
	6.2.3.5.3 Superoxide dismutase (SOD)	65
	6.2.3.5.4 Catalase	65
	6.2.3.6 Active avoidance learning	66
	6.2.4 Statistical Analysis	66
6.3	RESULTS	66
	6.3.1 Effect of Polyherbal formulation on brain neurotransmitters	66
	6.3.2 Effect of Polyherbal formulation on antioxidant levels	67
	6.3.3 Effect of Polyherbal formulation on cognitive function	68
	6.3.4 Effect of Polyherbal formulation on AchE level	69
	6.4.5 Effect of Polyherbal formulation on Lipofuscin level	70
6.4	DISCUSSION	70
6.5	CONCLUSION	73
7	EFFICACY OF POLYHERBAL FORMULATION ON HUMAN SUBJECTS	74
	7.1 INTRODUCTION	74
	7.2 METHODOLOGY	75

7.2.1	Study Design	75
7.2.2	Investigational products	75
7.2.3	Study groups	75
7.2.4	Inclusion criteria	75
7.2.5	Exclusion criteria	76
7.2.6	Withdrawal Criteria	77
7.2.7	Withdrawal from study protocol	76
7.2.8	Replacement of subjects	75
7.2.9	Prior and concomitant medication	76
7.2.10	Study procedure	76
7.2.11	Randomization and blinding	76
7.2.12	Assessment of safety and efficacy	77
7.2.13	Product information	78
7.2.16	Assessments	79
7.2.17	Statistical analysis	80
7.3	<b>RESULTS</b>	82
7.4	<b>DISCUSSION</b>	86
7.5	<b>CONCLUSION</b>	88
8	<b>SUMMARY</b>	89
	<b>REFERENCE</b>	90
	<b>APPENDICES</b>	115
	<b>LIST OF PUBLICATIONS</b>	129
	<b>VITAE</b>	130